ICU vs NKTR vs TPVG vs AKBA vs CPRX

For growth investors, Akebia Therapeutics, Inc.

(AKBA) is the stronger pick with 47. 5% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 9x trailing P/E (6. 5x forward), making it the more compelling value choice. Analysts rate Nektar Therapeutics (NKTR) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TriplePoint Venture Growth BDC Corp.

(TPVG) is the cheapest at 4. 9x versus Catalyst Pharmaceuticals, Inc. at 18. 6x. On forward P/E, TriplePoint Venture Growth BDC Corp. is actually cheaper at 6. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Catalyst Pharmaceuticals, Inc. wins at 0. 88x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Catalyst Pharmaceuticals, Inc.

(CPRX) delivered a total return of +545. 2%, compared to -98. 1% for SeaStar Medical Holding Corporation (ICU). Over 10 years, the gap is even starker: CPRX returned +48. 0% versus ICU's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TriplePoint Venture Growth BDC Corp.

(TPVG) is the lower-risk stock at 0. 83β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 122% more volatile than TPVG relative to the S&P 500. On balance sheet safety, Catalyst Pharmaceuticals, Inc. (CPRX) carries a lower debt/equity ratio of 0% versus 7% for Akebia Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Akebia Therapeutics, Inc.

(AKBA) is pulling ahead at 47. 5% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Akebia Therapeutics, Inc. grew EPS 93. 7% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, CPRX leads at 40. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus -183. 9% for SeaStar Medical Holding Corporation — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -132. 2% for ICU. At the gross margin level — before operating expenses — ICU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Catalyst Pharmaceuticals, Inc. (CPRX) is the more undervalued stock at a PEG of 0. 88x versus TriplePoint Venture Growth BDC Corp. 's 6. 41x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, TriplePoint Venture Growth BDC Corp. (TPVG) trades at 6. 5x forward P/E versus 16. 6x for Catalyst Pharmaceuticals, Inc. — 10. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AKBA: 239. 0% to $4. 00.

In this comparison, TPVG (17.

1% yield) pays a dividend. ICU, NKTR, AKBA, CPRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 83), 17. 1% yield). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TPVG: +93. 3%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ICU (Healthcare) and NKTR (Healthcare) and TPVG (Financial Services) and AKBA (Healthcare) and CPRX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ICU is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock; AKBA is a small-cap high-growth stock; CPRX is a small-cap high-growth stock. TPVG pays a dividend while ICU, NKTR, AKBA, CPRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.